Cargando…

Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma

Detalles Bibliográficos
Autores principales:	Alkhateeb, Hassan B., Mohty, Razan, Greipp, Patricia, Bansal, Radhika, Hathcock, Matthew, Rosenthal, Allison, Murthy, Hemant, Kharfan-Dabaja, Mohamed, Bisneto Villasboas, Jose C., Bennani, Nora, Ansell, Stephen M., Patnaik, Mrinal M., Litzow, Mark R., He, Rong, Chen, Dong, Al-Kali, Aref, Kenderian, Saad S., Lin, Yi, Shah, Mithun Vinod
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325766/ https://www.ncbi.nlm.nih.gov/pubmed/35882844 http://dx.doi.org/10.1038/s41408-022-00707-4

Ejemplares similares

S263: CYTOPENIAS, AGE AND CAR-HEMATOTOX SCORE PREDICT THE DEVELOPMENT OF POST CAR T-CELL THERAPY-RELATED MYELOID NEOPLASMS
por: Gurney, Mark, et al.
Publicado: (2023)

Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs
por: Ghorab, Ahmad, et al.
Publicado: (2022)

CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma
por: Mohty, Razan, et al.
Publicado: (2022)

Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation
por: Joshi, Maansi, et al.
Publicado: (2021)

Procalcitonin as a biomarker for predicting bacterial infection in chimeric antigen receptor T‐cell therapy recipients
por: Powell, Marissa Z., et al.
Publicado: (2023)

Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms
por: Shah, Mithun Vinod, et al.
Publicado: (2022)

Barriers to enrollment in clinical trials of patients with aggressive B-cell NHL that progressed after CAR T-cell therapy
por: Bezerra, Evandro D., et al.
Publicado: (2022)

Pre-lymphodepletion & infusion endothelial activation and stress index as predictors of clinical outcomes in CAR-T therapy for B-cell lymphoma
por: Acosta-Medina, Aldo A., et al.
Publicado: (2023)

Outcomes following venetoclax‐based treatment in therapy‐related myeloid neoplasms
por: Shah, Mithun Vinod, et al.
Publicado: (2022)

Treatment outcome of clonal cytopenias of undetermined significance: a single-institution retrospective study
por: Xie, Zhuoer, et al.
Publicado: (2021)

Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma
por: Parrondo, Ricardo D., et al.
Publicado: (2022)

Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy
por: Gangat, Naseema, et al.
Publicado: (2023)

Axicabtagene Ciloleucel in the Management of Follicular Lymphoma: Current Perspectives on Clinical Utility, Patient Selection and Reported Outcomes
por: Mohty, Razan, et al.
Publicado: (2023)

Consolidative radiotherapy for residual fluorodeoxyglucose activity on day +30 post CAR T-cell therapy in non-Hodgkin lymphoma
por: Saifi, Omran, et al.
Publicado: (2023)

Therapeutic Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Allogeneic Hematopoietic Cell Transplantation and Novel Therapies
por: Kharfan-Dabaja, Mohamed A., et al.
Publicado: (2019)

Clinical and biological characteristics and prognostic impact of somatic GATA2 mutations in myeloid malignancies: a single institution experience
por: Nanaa, Ahmad, et al.
Publicado: (2021)

P580: CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH WT1 MUTATED MYELOID NEOPLASMS: MAYO CLINIC EXPERIENCE
por: Basmaci, Rami, et al.
Publicado: (2023)

Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events
por: Abdelmagid, Maymona G., et al.
Publicado: (2023)

Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome
por: Al-Kali, Aref, et al.
Publicado: (2023)

U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity
por: Badar, Talha, et al.
Publicado: (2023)

Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma
por: Wiedmeier-Nutor, Julia Erin, et al.
Publicado: (2022)

Comparative study of therapy‐related and de novo adult b‐cell acute lymphoblastic leukaemia
por: Abdel Rahman, Zaid H., et al.
Publicado: (2021)

Outcomes of allogeneic transplant in patients with DDX41 mutated myelodysplastic syndrome and acute myeloid leukemia
por: Baranwal, Anmol, et al.
Publicado: (2022)

Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia
por: Gangat, Naseema, et al.
Publicado: (2022)

Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms
por: Alkhateeb, Hassan B., et al.
Publicado: (2022)

P734: CLONAL HEIRARCHY AND HETEROGENEITY IN STAG2M MYELOID NEOPLASMS: THE MAYO CLINIC EXPERIENCE
por: Katamesh, Bahga, et al.
Publicado: (2023)

P1346: THE IMPACT OF CYTOTOXIC THERAPY ON THE RISK OF PROGRESSION AND DEATH IN PATIENTS WITH CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE.
por: Marissa, LI, et al.
Publicado: (2023)

Clinical and prognostic impact of STAG2 mutations in myeloid neoplasms: the Mayo Clinic experience
por: Katamesh, Bahga, et al.
Publicado: (2022)

P747: CLINICAL CHARACTERISTICS AND OUTCOME OF EZH2-MUTATED MYELOID NEOPLASMS: MAYO CLINIC EXPERIENCE
por: Oum, Muhamad, et al.
Publicado: (2023)

Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma
por: Nadiminti, Kalyan, et al.
Publicado: (2021)

Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma
por: Wiedmeier, Julia E., et al.
Publicado: (2021)

Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blast-phase myeloproliferative neoplasm
por: Gangat, Naseema, et al.
Publicado: (2022)

Identification of adult Philadelphia-like acute lymphoblastic leukemia using a FISH‐based algorithm distinguishes prognostic groups and outcomes
por: Abdel-Rahman, Zaid H., et al.
Publicado: (2021)

P722: CHARACTERISATION OF PHF6 MUTATIONS IN MYELOID NEOPLASMS: THE MAYO CLINIC EXPERIENCE
por: Sai Mittapalli, Amrutha, et al.
Publicado: (2023)

High EASIX score is an independent predictor of non-relapse mortality in patients with CMML undergoing allogeneic stem cell transplant
por: Baranwal, Anmol, et al.
Publicado: (2022)

Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents
por: Johnson, Isla M., et al.
Publicado: (2022)

Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia
por: Pophali, Prateek, et al.
Publicado: (2020)

Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT
por: Breen, William G., et al.
Publicado: (2022)

Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma
por: Wiedmeier-Nutor, Julia E., et al.
Publicado: (2023)

TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms
por: Shah, Mithun Vinod, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7fkk0gogi184pu3cp63j01aep8